The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Eli Lilly plans to acquire psychedelics specialist AtaiBeckley through a multibillion-dollar deal that shows big pharma’s growing endorsement of a once-dimissed, now rapidly emerging research field.

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s ...

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, ...